Enliven Therapeutics (ELVN) Income from Continuing Operations (2019 - 2026)
Enliven Therapeutics (ELVN) reported Income from Continuing Operations of 27927000.0 for Q1 2026, up 12.11% on a YoY basis from 24909708.13 in Q1 2025, and up 18.82% sequentially from 34402000.0 in Q4 2025.
Enliven Therapeutics (ELVN) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 8 years of Income from Continuing Operations data on file, last reported at 27927000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 12.11% year-over-year to 27927000.0; the trailing twelve-month figure through Mar 2026 stood at 117137000.0 (down 5.73% YoY), and the FY2025 full-year result was 147462000.0, up 15.24% from the prior year.
- Income from Continuing Operations advanced to 27927000.0 in Q1 2026, from 34402000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 8897000.0 in Q1 2022 to a low of 58421000.0 in Q4 2023.
- A 5-year average of 25473352.94 and a median of 26072000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 120.32% in 2023 and surged 53.89% in 2024, its largest moves.
- Tracing ELVN's Income from Continuing Operations over 5 years: stood at 29714000.0 in 2022, then sank by 96.61% to 58421000.0 in 2023, then surged by 53.89% to 26940000.0 in 2024, then declined by 27.7% to 34402000.0 in 2025, then climbed by 18.82% to 27927000.0 in 2026.
- Business Quant data shows ELVN's Income from Continuing Operations at 27927000.0 in Q1 2026, 34402000.0 in Q4 2025, and 25610000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | -27.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.93 Mn |
| Dec 31, 2025 | -34.40 Mn |
| Sep 30, 2025 | -25.61 Mn |
| Jun 30, 2025 | -29.20 Mn |
| Mar 31, 2025 | -31.78 Mn |
| Dec 31, 2024 | -26.94 Mn |
| Sep 30, 2024 | -27.15 Mn |
| Jun 30, 2024 | -24.92 Mn |
| Mar 31, 2024 | -26.07 Mn |
| Dec 31, 2023 | -58.42 Mn |
| Sep 30, 2023 | -24.67 Mn |
| Jun 30, 2023 | -20.25 Mn |
| Mar 31, 2023 | -16.44 Mn |
| Dec 31, 2022 | -29.71 Mn |
| Sep 30, 2022 | -11.20 Mn |
| Jun 30, 2022 | -9.46 Mn |
| Mar 31, 2022 | -8.90 Mn |
| Dec 31, 2021 | -14.38 Mn |
| Sep 30, 2021 | -13.91 Mn |
| Jun 30, 2021 | -17.00 Mn |